Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 576 participants.

Also called NCT01760291

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose prevention
Phase
Not applicable
Enrolled
  • 576 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01760291
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01760291. Allocation not applicable; no masking; primary purpose prevention. Start 2012-09 (registry gives no type); primary completion 2019-04 (actual). Results posted on 2021-11-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology
Acronym
CAP2
Intervention (Device)
WATCHMAN LAA Closure Technology
Lead sponsor
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct01760291
Content hash
6e066686d4d039bbe6b4da2f92c353009475271115671322a3e9449e32a9c0b8